CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

D Sarker, S Blagden, N Cook, TR Evans, R Plummer, A Angelakas, S Bashir, S El Badri, L Mavroeidis, C Morton, A Muhith, M White, R Dixon, E Garric, J Mann, I Matthews, U Banerji

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)CT094-CT094
Number of pages3
JournalCancer Research
Issue number8_Supplement
Publication statusPublished - 15 Apr 2023

Cite this